September 26, 2025
Eli Lilly’s Oral SERD Inluriyo Approved by FDA for ESR1-Mutated Breast Cancer
Eli Lilly; Inluriyo; oral SERD; imlunestrant; FDA approval; ESR1 mutation; metastatic breast cancer; estrogen receptor positive; HER2-negative; EMBER-3 trial
Trump Administration Teases MFN Drug Pricing Rule as Commitment Deadline Looms for Companies
Trump administration; Most-Favored-Nation (MFN) pricing; drug pricing; executive order; pharmaceutical manufacturers; Medicaid; direct-to-consumer sales; price parity; commitment deadline; tariffs; international reference price
Thyme Care Raises $97 Million Series D to Drive AI-Powered Oncology Care at $1B Valuation
Thyme Care; cancer care; Series D funding; AI orchestration; oncology ecosystem; value-based care; patient navigation; strategic investors; unicorn startup; healthcare technology
Kai Beckmann Appointed as Successor to Merck KGaA CEO Belén Garijo, Effective May 2026
Merck KGaA; Kai Beckmann; Belén Garijo; CEO Succession; Electronics Business; Executive Board; Leadership Transition; Healthcare sector; Corporate governance; Strategic transformation